Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa-Part A: A Randomized Trial of Ring Vaccination to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa. Part B- Safety and immunogenicity of VSV¿G/ZEBOV-GP among Frontline Workers

Next Previous
Trial Profile

A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa-Part A: A Randomized Trial of Ring Vaccination to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa. Part B- Safety and immunogenicity of VSV¿G/ZEBOV-GP among Frontline Workers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 05 Oct 2022 Results of post-hoc pooled analysis of 3 studies(PREVAIL:NCT02344407; FLW: PACTR201503001057193; STRIVE:NCT02378753) published in the Vaccine
  • 25 Oct 2020 Results of post-hoc pooled analysis of 3 studies (Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL)), presented at the IDWeek 2020.
  • 19 Dec 2019 According to a Food and Drug Administration media release, the Food and Drug Administration (FDA) has approved Ervebo, a vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older.The approval of Ervebo is supported by this study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top